SFN significantly attenuated common symptoms of metabolic disorder that are associated with diabetes in Nrf2+/+ mice but not in Nrf2−/− mice, indicating that SFN operated via specific activation of the Nrf2 pathway. Here, NFE2L2 is linked to metabolic disease.